User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

6988

Interactions with Platform & by Email *

INTERACTIONS

1118

Unique # Participated *

PARTICIPANTS

210

Responses Validated *

VALIDATIONS

45

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Bipolar Disorder Facts.....II-1
A Market with Unmet Medical Needs.....II-1
1$100
   A Major Burden on Society.....II-2
Current and Future Analysis.....II-2
Patent Expiries Depress Market Growth.....II-2
1$100
   Patent Expiries of Major Bipolar Disorder Drugs.....II-3
Loss of Exclusivity to Continue.....II-3
Poor Pipeline Dims Prospects for Market Growth.....II-3
A Few Bright Spots.....II-3
1$100
   Opportunities and Challenges.....II-4
The Clinicians’ Quest for The Best - Seroquel XR.....II-4
1$100
   Children and Teens – The Targets or the Beneficiaries!.....II-5
Adverse Events - A Major Issue with Antipsychotics.....II-5
Side Effects Influence Prescription Trends.....II-5
2$125
   A Market Sans Competition.....II-7
Table 1: Bipolar Disorder Drugs Market (2009): Five Major Companies with Marketed Products (includes corresponding Graph/Chart).....II-7
Antipsychotics – The Mainstay Therapy.....II-7
1$350
   Table 2: Leading Players in Global Antipsychotic Drugs Market (2008): Annual Sales and Market Share Breakdown for Eli Lilly, AstraZeneca, Johnson & Johnson, Bristol-Myers Squibb, GlaxoSmithKline, and Pfizer (includes corresponding Graph/Chart).....II-8
Antidepressants.....II-8
1$350
   Table 3: Leading Drugs in the Global Antidepressants Market (2008): Revenues and Market Share Breakdown for Effexor, Cymbalta, Lexapro, Paxil/Wellbutrin, Zoloft and Remeron (includes corresponding Graph/Chart).....II-9
Antiepileptics - Prescriptions Continue Despite Warning.....II-9
1$350
   Select Antiepileptics with Approved Bipolar Disorder Indications.....II-10
Table 4: Leading Players in the Global Antiepileptics Market (2008): Revenue in US$ Million and Market Share Breakdown for Pfizer, Johnson & Johnson, UCB Pharma, Abbott, GlaxoSmithKline and Others (includes corresponding Graph/Chart).....II-10
1$350
   Abilify (Aripiprazole).....II-11
Geodon/Zeldox (Ziprasidone).....II-11
Invega (Paliperidone).....II-11
Lamictal (Lamotrigine).....II-11
1$100
   Risperdal (Risperidone).....II-12
Risperdal® Consta® (Risperidone).....II-12
1$100
   Saphris (Asenapine).....II-13
Seroquel (Quetiapine).....II-13
Seroquel XR.....II-13
Zyprexa (Olanzapine).....II-13
1$100
   Other Drugs.....II-14
Depakine (Sodium Valproate).....II-14
Depakote/ Depakote ER (Divalproex Sodium).....II-14
Tegretol (Carbamazepine).....II-14
1$100
   A Few Battle Big Challenges.....II-15
Drug Development Pipeline for Select Bipolar Disorder Candidates.....II-15
1$100
   Table 5: Bipolar Disorder Drugs (2009) - Select Companies with Products in Late Stage Clinical Development (Phase II, III, Pending Approvals) (includes corresponding Graph/Chart).....II-16
A Review of Select Leading Pipeline Candidates.....II-16
Lurasidone (SM-13,496).....II-16
Zomaril.....II-16
Nuvigil (armodafinil).....II-16
RG2417 (Uridine).....II-16
1$350
   RGH-188 (Cariprazine).....II-17
AZ - 004 (Staccato Loxapine).....II-17
Lu AA39959.....II-17
Lu AA34893.....II-17
1$100
   Introduction.....II-18
History.....II-18
1$100
   Causes of Bipolar Disorder.....II-19
Triggers.....II-19
Episodes in a Bipolar Disorder.....II-19
1$100
   Classification of Bipolar Disorder.....II-20
Bipolar Disorder Classification.....II-20
Symptoms of Various Types of Bipolar Disorder.....II-20
Mania.....II-20
1$100
   Hypomania.....II-21
Mixed State.....II-21
Depression.....II-21
1$100
   Additional Symptoms of Bipolar Episode.....II-22
Treatment of Bipolar Disorder.....II-22
Psychosocial Treatments.....II-22
1$100
   Hospitalization for Extreme Cases.....II-231$100
   Cephalon Announces Promising Phase II Clinical Results of NUVIGIL.....II-24
Repligen Commences Phase IIB Trial of RG2417.....II-24
Forest and Gedeon Richter Announce Favorable Phase II Results for Cariprazine.....II-24
1$100
   Alexza Commences Preliminary Phase 3 Trail with Staccato® Loxapine.....II-25
Dainippon Sumitomo to Conduct Clinical Study for Lurasidone.....II-25
1$100
   AstraZeneca Introduces Seroquel XR® in North America.....II-26
AstraZeneca Introduces Seroquel XR in Europe.....II-26
Wockhardt to Roll Out Divalproex ER Tablets.....II-26
FDA Approves SEROQUEL for Paediatric Treatment of Schizophrenia and Bipolar
  Disorder.....II-26
1$100
   FDA Approves Eli Lilly's Zyprexa for Schizophrenia and Bipolar Indications.....II-27
Pfizer Canada Receives Approval from Health Canada for ZELDOX.....II-27
Ortho-McNeil-Janssen Receives FDA Approval for RISPERDAL® CONSTA®.....II-27
FDA Grants Approval to Eurand for EUR-1048.....II-27
Merck/Schering-Plough Receives EMEA Approval for SYCREST®.....II-27
1$100
   FDA Approves SAPHRIS® for Treatment of Mixed/Manic Episodes of Bipolar Disorder and for
  Acute Treatment of Schizophrenia in Adults.....II-28
FDA Grants Marketing Approval to Glenmark for Lithium Carbonate Capsules.....II-28
Ranbaxy Australia Receives Approval from Therapeutic Goods Administration.....II-28
Servier Obtains Approval for Valdoxan®/Thymanax®.....II-28
Pfizer Canada Receives Approval from Health Canada for ZELDOX Drug.....II-28
1$100
   Pfizer Obtains Extended Approval for Geodon.....II-29
FDA Considers Approval of Psychiatric Medications for Children.....II-29
FDA Weighs Zyprexa for Two Juvenile Indications.....II-29
Caraco Pharmaceutical Introduces Divalproex Sodium Delayed Release Tablets.....II-29
1$100
   BMS and Otsuka Obtain European Marketing Approval for ABILIFY® for Manic
  Episodes.....II-30
ABILIFY® Obtains Extended Indications in Schizophrenia and Bipolar I Disorder.....II-30
AstraZeneca Receives European MRP Approval for SEROQUEL and SEROQUEL XR.....II-30
1$100
   FDA Approves Seroquel XR® Extended Release Tablets.....II-31
Mylan Pharmaceuticals Receives FDA Approval for Risperidone Tablets USP.....II-31
Depakote Generic Drug Receives FDA Approval.....II-31
Noven Pharmaceuticals Receives FDA Approval for Stavzor™.....II-31
BMS and Otsuka Receive FDA Approval for ABILIFY®.....II-31
Lupin Obtains FDA Approval for Divalproex Sodium Delayed-Release Tablets.....II-31
1$100
   Orchid Chemicals Obtains FDA Approval for Divalproex Sodium Delayed.....II-32
Noven Pharmaceuticals Receives FDA Approval for Stavzor Capsules.....II-32
Sun Pharmaceutical Industries Receives USFDA Approval for Depakote Divalproex Sodium
  Tablets.....II-32
1$100
   Abbott Takes Over Solvay Pharmaceuticals.....II-33
Merck & Co. Merges with Schering-Plough.....II-33
Pfizer Acquires Wyeth.....II-33
Hisamitsu Pharmaceutical and Hisamitsu U.S. Take Over Noven Pharmaceuticals.....II-33
1$100
   Avacta Group Acquires TheraGenetics.....II-34
BMS and Otsuka Extend their Agreement on Ability.....II-34
ADA Technologies to Develop Home Lithium-Monitor for Bipolar Disorder.....II-34
Repligen Licenses Global Rights for Bipolar Disorder Treatment.....II-34
SUN Pharmaceutical Industries to Divest Assets and Rights of Generic Drugs.....II-34
1$100
   AstraZeneca Signs Agreement with Abraxis BioScience.....II-35
Roche Holding to Acquire Memory Pharmaceuticals.....II-35
Scientists Find Common Genetic Profile between BPD and Schizophrenia.....II-35
Wyeth Terminates Bifeprunox Accord with Solvay.....II-35
1$100
   Noven Pharmaceuticals Takes Over JDS Pharmaceuticals.....II-361$100
   Abbott Laboratories, Inc. (US).....II-37
AstraZeneca PLC (UK).....II-37
Bristol-Myers Squibb Company (US).....II-37
1$100
   Cephalon, Inc. (USA).....II-38
Dainippon Sumitomo Pharma Co. Ltd. (Japan).....II-38
1$100
   Eli Lilly and Company (US).....II-39 1$100
   Table 6: Eli Lilly’s Leading Products (2009): Global Revenues in US$ Billion by Product - Zyprexa, Cymbalta, Humalog, Alimta, Cialis, Gemzar, Evista and Humulin (includes corresponding Graph/Chart).....II-40
Forest Laboratories, Inc. (US).....II-40
Gedeon Richter PLC (Hungary).....II-40
1$350
   GlaxoSmithKline PLC (UK).....II-41
H. Lundbeck A/S (Denmark).....II-41
Janssen Pharmaceutica, Inc. (US).....II-41
1$100
   Parent Company Profile - Johnson and Johnson Company (US).....II-42
Merck & Co., Inc. (US).....II-42
Otsuka America Pharmaceutical Inc. (US).....II-42
1$100
   Pfizer, Inc. (US).....II-43
Repligen Corporation (US).....II-43
1$100
   Validus Pharmaceuticals, Inc. (US).....II-441$100
   Table 7: World Recent Past, Current & Future Analysis for Bipolar Disorder Drugs by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-451$350
   Table 8: World 10-Year Perspective for Bipolar Disorder Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-461$350
   Table 9: World Recent Past, Current & Future Analysis for Bipolar Disorder Drugs by Therapeutic Class - Atypical Anti-Psychotics, and Other Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-471$350
   Table 10: World 10-Year Perspective for Bipolar Disorder Drugs by Therapeutic Class - Percentage Breakdown of Dollar Sales for Atypical Anti-Psychotics, and Other Therapeutics for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-481$350
   A. Market Analysis.....III-1
Current and Future Analysis.....III-1
Bipolar Disorder Facts.....III-1
Major Trends.....III-1
Mental Healthcare Expenditure Rising in the US.....III-1
1$75
   Antidepressants Grow as First-line Therapy for New Patients.....III-2
Treatment for Bipolar Disorder Differs Based on Physician Specialty.....III-2
American Children Prescribed More Psychotropic Drugs than European Children.....III-2
1$75
   Product Launches.....III-31$75
   Drug Approvals.....III-44$150
   Strategic Corporate Developments.....III-83$125
   Key Players.....III-11
Abbott Laboratories, Inc......III-11
Bristol-Myers Squibb Company.....III-11
1$75
   Eli Lilly and Company.....III-12 1$75
   Table 11: Eli Lilly’s Leading Products (2009): Breakup of Global Revenues in US$ Billion by Product - Zyprexa, Cymbalta, Humalog, Alimta, Cialis, Gemzar, Evista and Humulin (includes corresponding Graph/Chart).....III-13
Forest Laboratories, Inc......III-13
Janssen Pharmaceutica, Inc......III-13
1$200
   Merck & Co., Inc......III-14
Otsuka America Pharmaceutical, Inc......III-14
Pfizer, Inc......III-14
1$75
   Repligen Corp......III-15
Validus Pharmaceuticals, Inc......III-15
1$75
   B. Market Analytics.....III-16
Table 12: US Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-16
1$200
   A. Market Analysis.....III-17
Current and Future Analysis.....III-17
Product Launch.....III-17
Drug Approvals.....III-17
2$100
   B. Market Analytics.....III-19
Table 13: European Recent Past, Current & Future Analysis for Bipolar Disorder Drugs by Geographic Region - France, Germany, Italy, the UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-19
1$200
   Table 14: European 10-Year Perspective for Bipolar Disorder Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, the UK, Spain, and Rest of Europe Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....III-201$200
   A. Market Analysis.....III-21
Current and Future Analysis.....III-21
B. Market Analytics.....III-21
Table 15: French Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-21
1$200
   A. Market Analysis.....III-22
Current and Future Analysis.....III-22
B. Market Analytics.....III-22
Table 16: German Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-22
1$200
   A. Market Analysis.....III-23
Current and Future Analysis.....III-23
B. Market Analytics.....III-23
Table 17: Italian Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-23
1$200
   A. Market Analysis.....III-24
Current and Future Analysis.....III-24
Treatment Overview.....III-24
List of Licensed Drugs for Bipolar Disorder Treatment.....III-24
1$75
   Lithium and Valproate Semisodium – Prescription Trends.....III-25
Strategic Corporate Development.....III-25
Key Players.....III-25
AstraZeneca PLC.....III-25
1$75
   GlaxoSmithKline PLC.....III-26
B. Market Analytics.....III-26
Table 18: The UK Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-26
1$200
   A. Market Analysis.....III-27
Current and Future Analysis.....III-27
B. Market Analytics.....III-27
Table 19: Spanish Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-27
1$200
   A. Market Analysis.....III-28
Current and Future Analysis.....III-28
Key Players.....III-28
Gedeon Richter PLC (Hungary).....III-28
H. Lundbeck A/S (Denmark).....III-28
1$75
   B. Market Analytics.....III-29
Table 20: Rest of Europe Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-29
1$200
   A. Market Analysis.....III-30
Current and Future Analysis.....III-30
Australia.....III-30
Bipolar Disorder Facts.....III-30
Product Approval.....III-30
1$75
   B. Market Analytics.....III-31
Table 21: Asia-Pacific Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-31
1$200
   A. Market Analysis.....III-32
Current and Future Analysis.....III-32
Product Approval.....III-32
Key Player.....III-32
Dainippon Sumitomo Pharma Co. Ltd. (Japan).....III-32
1$75
   B. Market Analytics.....III-33
Table 22: Rest of World Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-33
1$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com